儿童和青少年人类免疫缺陷病毒相关肺结核中抗逆转录病毒治疗启动的最佳时机
该回顾性研究纳入2013至2020年博茨瓦纳、斯威士兰、马拉维、莱索托、坦桑尼亚和乌干达的Baylor卓越中心中0-19岁接受肺结核治疗的未启动抗逆转录病毒治疗(ART)的儿童和青少年HIV感染者774例,分析ART启动时机与全因死亡风险的关系。调整Cox模型显示,从未启动ART者较在结核治疗开始后2周至2个月启动ART者1年死亡风险升高(aHR 2.67,95%CI 1.03-6.94),而2周内启动者与2周至2个月启动者死亡风险无显著差异(aHR 1.02,95%CI 0.55-1.89)。
要点
- 在结核治疗开始后2周内启动ART的儿童和青少年HIV感染者,与2周至2个月启动者相比,死亡风险无显著差异(aHR 1.02,95%CI 0.55-1.89)。
- 从未启动ART者较在2周至2个月启动ART者1年死亡风险升高(aHR 2.67,95%CI 1.03-6.94)。
- 该回顾性研究结果支持世界卫生组织(WHO)关于儿童和青少年HIV感染者在启动结核治疗后2周内启动ART的建议。
核心结论
- 该回顾性研究显示,在结核治疗开始后2周内启动ART的儿童和青少年HIV感染者死亡风险未增加;鉴于ART的广泛健康益处,该证据支持WHO关于在启动结核治疗后2周内启动ART的建议。
研究设计与样本
- 回顾性研究,数据来自博茨瓦纳、斯威士兰、马拉维、莱索托、坦桑尼亚和乌干达的Baylor卓越中心2013至2020年的电子病历。
- 纳入0-19岁、未启动ART、接受HIV相关肺结核治疗的儿童和青少年HIV感染者774例。
- 按启动ART时机分组:<2周(n=266)、2周至2个月(n=398)、>2个月(n=66)、未启动ART(n=44)。
- 主要结局为全因死亡,采用未调整Kaplan-Meier曲线和Cox比例风险模型分析。
主要发现
- 调整Cox比例风险模型显示,从未启动ART者较在结核治疗开始后2周至2个月启动ART者,结核治疗开始后1年死亡风险升高(aHR 2.67,95%CI 1.03-6.94)。
- 在结核治疗开始后<2周启动ART者与2周至2个月启动ART者相比,死亡风险无显著差异(aHR 1.02,95%CI 0.55-1.89)。
临床怎么用
- 作者指出,鉴于ART的广泛健康益处,该证据支持WHO近期关于儿童和青少年HIV感染者在启动结核治疗后2周内启动ART的建议。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is insufficient evidence in children and adolescents with human immunodeficiency virus (CAHIV) to guide the timing of antiretroviral treatment (ART) initiation after starting treatment for pulmonary tuberculosis (pTB). To address this knowledge gap, we evaluated the risk of mortality associated with timing of ART initiation in ART-naive CAHIV treated for pTB. METHODS: Data were extracted from electronic medical records of ART-naive patients, aged 0-19 years, who were treated for HIV-associated pTB at Baylor Centers of Excellence in Botswana, Eswatini, Malawi, Lesotho, Tanzania, or Uganda between 2013 and 2020. Data were analyzed against a primary outcome of all-cause mortality with unadjusted Kaplan-Meier curves and Cox proportional hazard models. RESULTS: The study population included 774 CAHIV with variable intervals to ART initiation after starting TB treatment: <2 weeks (n = 266), 2 weeks to 2 months (n = 398), >2 months (n = 66), and no ART initiated (n = 44). Adjusted Cox proportional hazards models demonstrated increased mortality 1 year from TB treatment initiation in children never starting ART (adjusted HR [aHR]: 2.67; 95% CI: 1.03, 6.94) versus children initiating ART between 2 weeks and 2 months from TB treatment initiation. Mortality risk did not differ for the <2-weeks group (aHR: 1.02; 95% CI: .55, 1.89) versus the group initiating ART between 2 weeks and 2 months. CONCLUSIONS: This retrospective study demonstrated no increase in mortality among CAHIV initiating ART <2 weeks from TB treatment initiation. Given the broad health benefits of ART, this evidence supports the recent WHO recommendation for CAHIV to initiate ART within 2 weeks of initiating TB treatment.
引用
- Kay A, Mendez-Reyes J, Devezin T, et al. Optimal Timing of Antiretroviral Therapy Initiation in Children and Adolescents With Human Immunodeficiency Virus-Associated Pulmonary Tuberculosis. Clin Infect Dis. 2023. PMID: 36097966. doi:10.1093/cid/ciac765
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。